Cppi Cv Drug Patent Portfolio
Cppi Cv owns 1 orange book drug protected by 6 US patents Given below is the list of Cppi Cv's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6573293 | Pyrrole substituted 2-indolinone protein kinase inhibitors | 15 Aug, 2021 | Expired |
US7125905 | Pyrrole substituted 2-indolinone protein kinase inhibitors | 15 Aug, 2021 | Expired |
US7211600 | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds | 22 Jun, 2021 | Expired |
US6573293 | Pyrrole substituted 2-indolinone protein kinase inhibitors | 15 Feb, 2021 | Expired |
US7125905 | Pyrrole substituted 2-indolinone protein kinase inhibitors | 15 Feb, 2021 | Expired |
US7211600 | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds | 22 Dec, 2020 | Expired |
Latest Legal Activities on Cppi Cv's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cppi Cv.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2018 | US7211600 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 13 Mar, 2018 | US7125905 (Litigated) |
Patent Term Extension Certificate
Critical
| 06 Apr, 2016 | US6573293 (Litigated) |
Patent Term Extension Certificate
Critical
| 17 Nov, 2015 | US6573293 (Litigated) |
Notice of Final Determination -Eligible | 16 Jun, 2015 | US6573293 (Litigated) |
Notice of Final Determination -Eligible | 23 Apr, 2015 | US6573293 (Litigated) |
FDA Final Eligibility Letter
Critical
| 21 Jan, 2015 | US6573293 (Litigated) |
transaction for FDA Determination of Regulatory Review Period | 15 May, 2014 | US6573293 (Litigated) |
transaction for FDA Determination of Regulatory Review Period | 02 May, 2014 | US6573293 (Litigated) |
Second letter to regulating agency to determine regulatory review period | 05 Sep, 2013 | US6573293 (Litigated) |
Post Issue Communication - Certificate of Correction | 20 Mar, 2012 | US7211600 (Litigated) |
Letter from FDA or Dept of Agriculture re PTE application | 03 May, 2011 | US6573293 (Litigated) |
Initial letter Re: PTE Application to regulating agency | 02 Mar, 2010 | US6573293 (Litigated) |
Patent Term Extension Application under 35 USC 156 Filed | 17 Jul, 2009 | US6573293 (Litigated) |
Recordation of Patent Grant Mailed
Critical
| 01 May, 2007 | US7211600 (Litigated) |
Cppi Cv's Family Patents
Cppi Cv Drug List
Given below is the complete list of Cppi Cv's drugs and the patents protecting them.
1. Sutent
Sutent is protected by 6 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6573293
(Pediatric)
| Pyrrole substituted 2-indolinone protein kinase inhibitors |
15 Aug, 2021
(3 years ago)
| Expired |
US7125905
(Pediatric)
| Pyrrole substituted 2-indolinone protein kinase inhibitors |
15 Aug, 2021
(3 years ago)
| Expired |
US7211600
(Pediatric)
| Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
22 Jun, 2021
(3 years ago)
| Expired |
US6573293 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
15 Feb, 2021
(3 years ago)
| Expired |
US7125905 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
15 Feb, 2021
(3 years ago)
| Expired |
US7211600 | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
22 Dec, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sutent's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List